BioMarin Pharmaceutical Inc. (BMRN) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | 220.65M | 99.64M | 368.69M | 185.27M | 174.39M | 185.63M | 221.48M | 118.76M | 46.97M | 27.48M | 135.65M | 70.06M |
| Operating CF Margin % | 28.8% | 11.39% | 47.5% | 22.45% | 23.4% | 24.84% | 29.7% | 16.68% | 7.24% | 4.25% | 23.33% | 11.77% |
| Operating CF Growth % | 26.52% | -46.32% | 66.46% | 56% | 271.28% | 575.42% | 63.28% | 69.51% | 163.53% | 305% | -14.32% | 24.61% |
| Net Income | 105.53M | 139.11M | -30.74M | 426.22M | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M | 20.38M | 40.38M | 56.04M |
| Depreciation & Amortization | 16.41M | 20.44M | 18.49M | 18.56M | 22.07M | 23.61M | 19.01M | 26.46M | 27.35M | 26.86M | 25.68M | 25.42M |
| Stock-Based Compensation | 43.46M | 46.91M | 49.27M | 47.53M | 37.7M | 51.92M | 43.49M | 47.91M | 58.25M | 54.85M | 48.39M | 50.16M |
| Deferred Taxes | 9.22M | 613K | -13.65M | 33.34M | 28.43M | 42.39M | 12.17M | 1.25M | 285K | -24.84M | -15.03M | 1.25M |
| Other Non-Cash Items | 6.97M | -128.36M | 226.4M | -182.31M | -9.03M | 25.92M | 1.67M | 2.88M | -22.19M | 47.35M | -3.69M | -111K |
| Working Capital Changes | 39.07M | 20.93M | 118.93M | -158.07M | -90.46M | -83.15M | 39.06M | -66.92M | -105.39M | -97.12M | 39.92M | -62.7M |
| Change in Receivables | -7.16M | -120.68M | 48.75M | -98.53M | -57.59M | 72.55M | -74.38M | -52.7M | -3.39M | -58.49M | 13.89M | -7.04M |
| Change in Inventory | 44.49M | 218M | -26.33M | -48.13M | -24.34M | -34.27M | 18.15M | -30.59M | -16.82M | -59.11M | -41.47M | -42.38M |
| Change in Payables | 3.1M | -53.34M | 116.37M | 5.77M | -2.65M | -100.26M | 122.28M | 4.75M | -59.01M | 12.52M | 81.43M | 6.59M |
| Cash from Investing | 725.53M | -42.45M | -330.96M | -12.59M | -28.24M | 76.4M | -16.16M | 90.48M | -14.24M | -64.96M | -45.8M | 29.53M |
| Capital Expenditures | -20.92M | -40.72M | -33.75M | -17.1M | -16.77M | -19.53M | -18.46M | -21.33M | -26.1M | -36.7M | -23.42M | -21.58M |
| CapEx % of Revenue | 2.73% | 4.66% | 4.35% | 2.07% | 2.25% | 2.61% | 2.48% | 3% | 4.02% | 5.68% | 4.03% | 3.63% |
| Acquisitions | 0 | 0 | -285.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.06M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.97M | -2.37M | 0 | -266K | 0 | -769K | -1.57M | -512K | 2M | 0 | -24.06M | -1.15M |
| Cash from Financing | 813.17M | 3.16M | -2.17M | -4.6M | -38.78M | 2.86M | -499.13M | 12.61M | -42.79M | 10.84M | -788K | 11.96M |
| Debt Issued (Net) | 841.35M | 0 | 0 | 0 | 0 | 0 | -494.93M | -18K | -42K | -45K | -606K | -621K |
| Equity Issued (Net) | 0 | -31.07M | 7K | 7.71M | -38.78M | 0 | 0 | 0 | 0 | 14.8M | 4.36M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -38.78M | 0 | 0 | -38.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -28.18M | 34.23M | -2.18M | -12.31M | 0 | 2.86M | -4.2M | 12.63M | -42.75M | -3.92M | -4.54M | 12.58M |
| Net Change in Cash | 1.76B | 61.57M | 36.29M | 165.01M | 105.96M | 267.39M | -296.7M | 225.15M | -8.13M | -30.29M | 91.03M | 114.31M |
| Free Cash Flow | 199.73M | 58.92M | 340.24M | 168.17M | 157.63M | 165.33M | 200.31M | 96.92M | 12.87M | -9.21M | 112.23M | 47.33M |
| FCF Margin % | 26.07% | 6.74% | 43.84% | 20.37% | 21.15% | 22.12% | 26.86% | 13.61% | 1.98% | -1.43% | 19.31% | 7.95% |
| FCF Growth % | 26.71% | -64.36% | 69.86% | 73.51% | 1125.04% | 1894.51% | 78.48% | 104.77% | 113.04% | 68.85% | -7.9% | 67.9% |
| FCF per Share | 1.01 | 0.30 | 1.77 | 0.86 | 0.80 | 0.84 | 1.02 | 0.48 | 0.06 | -0.05 | 0.59 | 0.24 |
| FCF Conversion (FCF/Net Income) | 2.09x | -2.14x | -11.99x | 0.77x | 0.94x | 1.49x | 2.09x | 1.11x | 0.53x | 1.35x | 3.36x | 1.25x |
| Interest Paid | 0 | 0 | -65K | 3.64M | 0 | 3.71M | 1.53M | 3.71M | 1.42M | 3.66M | 1.47M | 3.74M |
| Taxes Paid | 0 | 0 | 7.82M | 52M | 10.39M | 21.18M | 13.2M | 20.58M | 2.3M | 21.63M | 23.5M | 23.82M |